Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.54 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | HSD17B13 | Q7Z5P4 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13218656 | 0.94 | ROCK2 (0.53) | ROCK2ROCK1EPHX2PPARGHDAC6 | |
| SCHEMBL2969531 | 0.84 | EPHX2 (0.52) | ROCK2ROCK1EPHX2PPARGHDAC6 | |
| SCHEMBL2927034 | 0.84 | EPHX2 (0.55) | ROCK2ROCK1EPHX2PPARG | |
| SCHEMBL2901231 | 0.78 | EPHX2 (0.53) | ROCK2ROCK1EPHX2PPARGMAPT | |
| SCHEMBL19260062 | 0.77 | RAB9A (0.52) | ROCK2ROCK1HDAC6ACHEHDAC2 | |
| SCHEMBL3025736 | 0.75 | ROCK2 (0.57) | ROCK2ROCK1EPHX2PPARGHDAC6 | |
| SCHEMBL3024704 | 0.75 | ROCK2 (0.47) | ROCK2ROCK1EPHX2PPARGHDAC6 | |
| SCHEMBL5419581 | 0.75 | ROCK2 (0.62) | ROCK2ROCK1EPHX2PPARGHDAC6 | |
| SCHEMBL13947519 | 0.75 | EPHX2 (0.66) | ROCK2ROCK1EPHX2PPARGHDAC6 | |
| SCHEMBL5209564 | 0.75 | EPHX2 (0.57) | ROCK2ROCK1EPHX2PPARGHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-10-14 | — | — | US | disclosed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261743-A1 | NOVEL SEH INHIBITORS AND THEIR USE | EPHX1, REN, NCEH1 | ROCK2 133/4885ROCK1 72/4885EPHX2 9/4885 |
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, FAH | ROCK2 396/4885ROCK1 226/4885EPHX2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.